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Abstract
AIM
To estimate the pharyngeal carriage rate of Neisseria 
meningitidis  (N. meningitidis), Streptococcus pneumoniae 
(S. pneumoniae) and Staphylococcus aureus (S. aureus) 
among Australian Hajj pilgrims.
METHODS
In 2014, surveillance was conducted in two phases among 
Australian Hajj pilgrims: The first phase during Hajj in 
Mina, and the second phase soon after returning home to 
Australia. Nasopharyngeal or oropharyngeal swabs were 
taken from participants then tested, firstly by nucleic acid 
testing, and also by standard culture.
RESULTS
Of 183 participants recruited in the first phase, 26 (14.2%) 
tested positive for S. pneumoniae ; 4 had received 
pneumococcal conjugate vaccine (PCV13). Only one 
tested positive for N. meningitidis  (W). Of 93 2nd phase 
samples cultured, 17 (18.3%) grew S. aureus , all me-
thicillin sensitive, 2 (2.2%) grew N. meningitidis  (on sub-
culture; one serotype B, one negative), and 1 (1%), from 
an unvaccinated pilgrim, grew S. pneumoniae.
CONCLUSION
Relatively high carriage of S. pneumoniae  and little 
meningococcal carriage was found. This indicates the 
importance of a larger study for improved infection 
surveillance and possible vaccine evaluation. 
Key words: Carriage; Conjugate vaccine; Staphylococcus 
aureus; Neisseria meningitidis; Streptococcus pneumoniae; 
Hajj
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: We conducted this pilot study to understand 
the impact of mass gatherings on pharyngeal carriage of 
potentially pathogenic bacteria and to assess the burden 
of pathogenic microorganisms resistant to antimicrobial 
agents among travellers returning to Australia following 
an overseas travel. This study demonstrates that a 
larger study is feasible and important to inform public 
health measures to prevent the transmission and limit 
emergence of antimicrobial resistant pathogens at mass 
gathering events such as the annual Hajj pilgrimage.
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INTRODUCTION
Hajj is one of the world’s largest annual mass gatherings, 
attracting approximately 2-3 million people each year 
from around the globe. During Hajj there is a high risk of 
communicable diseases, primarily due to overcrowding, 
shared accommodation and mingling of local and inter-
national pilgrims[1,2]. The importation of pathogens 
from arriving pilgrims may result in local transmission 
of infection within the Kingdom of Saudi Arabia (KSA). 
Similarly, there may be further dissemination of infectious 
diseases after pilgrims return home. 
Respiratory infections are of particular concern at Hajj; 
transmission may occur from symptomatic individuals or 
asymptomatic carriers[3,4]. In susceptible populations, the 
pharyngeal colonisation of pathogens may contribute to 
serious bacterial infections, including pneumonia, sepsis 
and meningitis[5]. Localised meningococcal outbreaks 
and their further dissemination have been linked to 
international travel, migration, attendance at Hajj and 
participation in sporting events[6-11]. Intercontinental 
spread of serogroup A meningococcal disease in 1987 
affected thousands of Hajj pilgrims globally; mandating 
bivalent meningococcal (A and C) vaccine for all Hajj 
pilgrims helped with disease control[7]. Investigation of the 
1992 meningococcal outbreak in Makkah, KSA showed 
an extremely high meningococcal carriage rate of 86% 
among devotees who attended congregational prayers 
in the Holy Mosque[12]. Following the Hajj-associated 
outbreaks of Neisseria meningitidis (N. meningitidis) W 
in 2000 and 2001, visas for entry into KSA for Hajj and 
Umrah pilgrims were changed to require the quadrivalent 
meningococcal vaccine (covering serogroups A, C, W and 
Y)[13,14].
Currently, respiratory infections are the most common 
illnesses during Hajj[15,16]. Cough is almost de rigeur, 
occurring virtually in all Hajj pilgrims[17,18]. Pneumonia 
is the leading cause of hospital admission during Hajj, 
with the commonest causative organisms being Strepto­
coccus pneumoniae (S. pneumoniae), Haemophilus 
influenzae, Klebsiella pneumoniae and Mycobacterium 
tuberculosis[19-21]. 
In a study of samples from nares, axilla, groins and 
open wounds of Hajj pilgrims, a 20.9% carriage rate 
of Staphylococcus aureus (S. aureus) was found. Of 
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these about 1.5% were methicillin resistant S. aureus 
(MRSA)[22]. In another study in four Makkah hospitals 
spanning twelve months from 2004-2005 that included 
the Hajj season, MRSA accounted for 199 of 512 (39%) 
S. aureus clinical isolates[23].
Inappropriate antimicrobial use during Hajj could 
result in the emergence of drug-resistant organisms, 
and antibiotic resistant respiratory organisms have been 
frequently isolated from Hajj pilgrims[24-26]. The potential 
for worldwide outbreak of infectious diseases caused by 
resistant microorganisms such as ciprofloxacin-resistant 
N. meningitidis, penicillin-resistant S. pneumoniae, 
MRSA and extended-spectrum beta-lactamase (ESBL) 
producing Gram negative bacteria is increasingly reco-
gnised[27-30]. Recently, there was a worrying report of 
the acquisition of extended-spectrum cephalosporin- 
and colistin-resistant Salmonella enterica in a returned 
French Hajj pilgrim[31].
The pharyngeal carriage of bacterial pathogens 
among Australian pilgrims has not been evaluated. 
Therefore, we performed two pilot studies, during and 
after Hajj, to estimate the pharyngeal carriage rate of 
N. meningitidis, S. pneumoniae and S. aureus among 
Australian Hajj pilgrims who attended Hajj in 2014, 
assessed antimicrobial susceptibility patterns and inve-
stigated the possible impact of preventive measures 
such as pre-travel vaccination and facemasks use.
MATERIALS AND METHODS
Enhanced surveillance was conducted in two phases 
among Australian pilgrims: The first phase involved 
recruiting pilgrims during their tent stay in Mina, Mak-
kah, KSA in the peak period of the Hajj 2014, and the 
second phase involved recruiting pilgrims after their 
return from Hajj to Australia (Figure 1).
First phase (during Hajj)
This study was explained to pilgrims in their tents. From 
those who consented, nasopharyngeal or oropharyngeal 
swabs were collected while in Mina from all participants 
on the fifth day of their stay in tents; in a subset of 
pilgrims who had respiratory symptoms (cough, sore 
throat and/or rhinorrhoea), swabs were also collected on 
the first day of recruitment. Following collection, flocked 
swabs were placed in universal transport medium (UTM) 
(Vircell). The swabs were transported approximately 
5 km on ice to the collaborating laboratory in Makkah 
where they were stored at -20 ℃ before being shipped 
under similar conditions to the testing laboratory in 
Australia. This carriage study was nested within an 
ongoing randomised controlled trial examining the 
efficacy of facemasks against respiratory viruses; this 
methodology is published[32].
Second phase (post-Hajj)
Within 2 mo of their return from Hajj, Australian pilgrims 
were consented for follow-up swabbing. Oropharyngeal 
swabs were collected in mosques, community centres, 
local events (such as “family fun” days) and participants’ 
residences in Greater Sydney, New South Wales. From 
each pilgrim, 2 oropharyngeal swabs were obtained 
First phase (during Hajj)
During Hajj
2-6 October 2014 
Mina, Makkah
193 flocked swabs were collected (n  = 183)
(10 participants swabbed twice)
Post-Hajj
Sydney, Australia
All tested by nucleic acid testing
Second phase (post-hajj)
Within 2 mo after Hajj
Sydney, Australia 
30 (out of 183) were 
followed up after Hajj
(n  = 30)
63 additional Hajj pilgrims 
from same groups were 
recruited (n  = 63)
Two swabs were taken from each participant
All tested by standard culture for growth of pneumococcal, 
staphylococcal and meningococcal organisms
Figure 1  Schematic diagram showing recruitment of pilgrims.
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using charcoal and non-charcoal Copan Amies agar gel 
swabs and transported to the laboratory on ice within 
four hours of collection.
Phenotypic identification of N. meningitidis, S. 
pneumoniae and S. aureus
Swabs collected during the second phase were directly 
plated onto mannitol aztreonam methicillin salt, chocolate 
and nalidixic acid (Oxoid, Basingstoke, England) and 
modified New York City (Becton Dickinson, Sparks, MD, 
United States) agar plates. Bacterial colonies growing 
following 24-48 h of incubation in 5% CO2 at 37 ℃ were 
identified using the Bruker Microflex LT (Bruker Daltonics 
Inc., Billerica, MA, United States) matrix-assisted laser 
desorption-ionization time-of-flight (MALDI-TOF) mass 
spectrometer. Antimicrobial susceptibility testing was 
performed using E-test (AB BIODISK, Solna, Sweden) 
or the BD Phoenix (Becton Dickinson) automated mi-
crobiology system. Serotyping of N. meningitidis was 
performed on all isolates using agglutination serum 
(Remel Europe Ltd., Dartford, England). 
Nucleic acid test for N. meningitidis and S. pneumoniae
Swabs collected during Hajj were vortexed in 3 mL of 
UTM. Nucleic acid (NA) was extracted from 250 µL of 
UTM sample using the Qiagen EZ1 Virus Mini kit on the 
Qiagen EZ1 Advanced XL instrument. NA was eluted 
in a final volume of 60 µL and stored at -80 ℃ prior to 
nucleic acid testing (NAT). 
NAT of S. pneumoniae
S. pneumoniae was detected using a modified version of 
an assay previously described[33], targeting a 101 base-pair 
segment of the autolysin-encoding (lytA) gene [forward 
primer, 5’-ACGCAATCTAGCAGATGAAGC-3’; reverse primer, 
5’-TGTTTGGTTGGTTATTCGTGC-3’; probe, 5’-6-carboxy-
fluorescein (FAM)-TTTGCCG AAAACGCTTGATACAGGG-
BHQ-1-3’].
Baseline fluorescence was determined using a fluo-
rescence reader (FluorTracker™, Stratagene, La Jolla, CA, 
United States) before amplification in the Mastercycler 
Gradient thermocycler (Eppendorf, Hamburg, Germany). 
The reaction mix was amplified at 95 ℃ × 15 min 
(96 ℃ × 10 s; 63 ℃ × 1 min) for 45 cycles and 72 ℃ 
× 2 min for one cycle. End point fluorescence was then 
determined using FluorTracker™, positive samples were 
defined as a minimum of 2 × increase in fluorescence. 
These results were confirmed by agarose gel electro-
phoresis on a 2% gel run at 200 volts for 40 min and 
stained with SYBR-Safe. 
NAT of N. meningitidis
N. meningitidis was detected using a previously des-
cribed assay[34], that uses a single amplification real-
time PCR targeting a 110 base-pair segment of the 
meningococcal capsular transfer gene, ctrA [forward 
primer, 5’-GCTGCGGTAGGTGGTTCAA-3’; reverse primer, 
5’-TTGTCGCGGATTTGCAACTA-3’; probe, 5’-6-carboxy-
fluorescein (FAM)-CATTGCCACGTGTCAGCTGCACAT-
BHQ-1-3’]. The reaction mix was amplified in a Roche 
LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, 
Germany) at 95 ℃ × 5 min (95 ℃ × 15 s, 60 ℃ × 1 min) 
× 45; 40 ℃ × 30 s with detection on the 640 nmol/L 
channel during elongation at 60 ℃.
NAT of N. meningitidis serogroup
Samples where N. meningitidis was detected were fur-
ther evaluated using a previously described molecular 
serotyping method[35]. Samples were tested using five 
single-plex conventional assays targeting different 
regions of the orf­2 and siaD genes which are specific 
for serotypes A, B, C, W and Y. The primer sequences 
are listed in Table 1. The reaction mixes were amplified 
at 95 ℃ × 15 min (95 ℃ × 30 s; 50 ℃/55 ℃ × 1 min; 
72 ℃ × 30 s) for 40 cycles and 72 ℃ × 5 min for one 
cycle. The resultant products were visualised by agarose 
gel electrophoresis on a 2% gel run at 200 volts for 40 
min and stained with SYBR-Safe.
Ethical approval
Ethics approval was granted by the Hunter New England 
Human Research Ethics Committee (HREC), Australia 
(Ref: HREC/13/HNE/265). To verify the vaccination 
records of pilgrims, data were cross-checked with another 
ongoing trial by our team with a separate ethics approval 
from the Hunter New England HREC (Ref13/05/15/3.05). 
Table 1  The primer sequences for Neisseria meningitidis
Serotype Gene target Primer sequences Product size (bp)
A orf-2 F: CGCAATAGGTGTATATATTCTTCC; 400
R: CGTAATAGTTTCGTATGCCTTCTT
B siaD F: GGATCATTTCAGTGTTTTCCACCA; 
R: GCATGCTGGAGGAATAAGCATTAA
450
C siaD F: TCAAATGAGTTTGCGAATAGAAGGT; 
R: CAATCACGATTTGCCCAATTGAC
250
W135 siaD F: CAGAAAGTGAGGGATTTCCATA; 
R: CACAACCATTTTCATTATAGTTACTGT
120
Y siaD F: CTCAAAGCGAAGGCTTTGGTTA; 
R: CTGAAGCGTTTTCATTATAATTGCTAA
120
Orf2: Open reading frame 2; siaD: Polysialyltransferase gene.
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RESULTS
A total of 246 pilgrims were recruited to this study: 183 
in the first phase during Hajj and 93 in the second phase 
after Hajj; 30 appeared in both groups (Figure 1). The 
median age for pilgrims was 40 years (range 12-67), 
126 (51.2%) were women (Tables 2 and 3).
First phase (during Hajj)
One hundred and ninety three samples were collected 
from 183 study participants. Ten participants provided 
two swabs, the first collected on their first day in Mina 
when symptomatic and second collected on their 5th 
day.
Twenty-six (14.2%) participants had S. pneumoniae 
detected by NAT (Table 3). Thirty-eight (20.8%) parti-
cipants had a confirmed history of receiving 13-valent 
pneumococcal conjugate vaccine (PCV13) within six 
months prior to travel. Of the 26 pilgrims who were PCR-
positive for S. pneumoniae, 4 reported receiving PCV13 
and the other 22 reported not receiving the vaccine. 
Of the 183 study participants only one (0.6%) tested 
positive for N. meningitidis (serogroup W). Receipt of 
quadrivalent polysaccharide meningococcal vaccine was 
reported by 144 (78.7%) participants - 39 (21.3%) 
reported receiving quadrivalent meningococcal conjugate 
vaccine. The pilgrim with positive N. meningitidis PCR 
reported receiving the polysaccharide vaccine. Seventy-
six (41.5%) participants reported using a facemask, 
while 92 (50.3%) reported not using a facemask at 
anytime during Hajj; the other 15 (8.2%) did not disclose 
if they used a facemask. The pneumococcal carriage rate 
was similar in those who used a facemask compared to 
those who did not [14.1% (13/92) vs 14.5% (11/76), P 
= 0.95]. There was no statistically significant difference 
in pneumococcal carriage rates based on age < 50 years 
(16.7% vs 11.5%, P = 0.3) or gender (female vs male = 
17.1% vs 9.7%, P = 0.2). The only pilgrim with positive N. 
meningitidis PCR reported not using a facemask during 
Hajj. 
Second phase (post-Hajj)
Of the oropharyngeal samples collected from 93 pil-
grims, S. aureus was isolated in 17 (18.3%), and all 
were methicillin susceptible (Table 3). N. meningitidis 
was isolated in two (2.2%) samples; on subculture, 
one was serotype B and sensitive to benzylpenicillin 
and cefotaxime, the other was negative on subculture. 
Both pilgrims reported receiving the quadrivalent me-
ningococcal polysaccharide vaccine. In this group 89 
(95.7%) reported receiving meningococcal quadrivalent 
vaccine before travelling to Hajj: 48 (51.6%) poly-
saccharide vaccine and 41 (44.1%) conjugate vaccine. 
Four (4.3%) did not recall their vaccination history but 
having attended Hajj before, were likely to have been 
vaccinated previously. 
S. pneumoniae was isolated from one pilgrim 
and it could not be serotyped and sensitivity was not 
done; this pilgrim had not been vaccinated against 
pneumococcus. Of the 93 participants in this group, 
38 (40.9%) reported receiving pneumococcal vaccine, 
PCV13 in all. Thirty-two (34.4%) reported using a face-
mask, 59 (63.4%) reported not using a facemask during 
Hajj and the other 2 (2.2%) did not disclose whether 
they used a facemask or not. Of 32 pilgrims who used 
a facemask, S. aureus was isolated from 8 (25%), and 
of 59 pilgrims who did not use a facemask S. aureus 
was isolated from 9 (15%) (P = 0.27). Both pilgrims 
from whom meningococci were isolated reported using 
a facemask, the pilgrim from whom pneumococcus 
was recovered did not disclose whether a facemask 
was used or not. There was no statistically significant 
difference in staphylococcal carriage rates based on age 
< 50 years (17.5% vs 23%, P = 0.6) or gender (male 
vs female = 20% vs 13%, P = 0.4). Sixteen (17.2%) 
Table 2  Demographics of participants (during and post-Hajj, 
n  = 246)
Attributes During Hajj n  (%) Post-Hajj n  (%)
Gender
  Female 111 (60.7)   30 (32.3)
  Male   72 (39.3)   63 (67.7)
Age in years  
  0-18 0 1 (1)
  19-34   38 (20.8)   17 (18.3)
  35-49   58 (31.7)   52 (55.9)
 50-64   28 (15.3)    8 (8.6)
  ≥ 65   1 (0.6) 0
  Did not disclose   58 (31.7)   15 (16.1)
Meningococcal vaccine uptake
  Not vaccinated 0    4 (4.3)
  Meningococcal polysaccharide 
  vaccine
144 (78.7)   48 (51.6)
  Meningococcal Conjugate 
  vaccine
  39 (21.3)   41 (44.1)
Pneumococcal vaccine uptake
  Not vaccinated 145 (79.2)   55 (59.1)
  Pneumococcal conjugate  
  vaccine (PCV13)
  38 (20.8)   38 (40.9)
Facemasks use
  Used facemasks   76 (41.5)   32 (34.4)
  Did not use facemasks   92 (50.3)   59 (63.4)
  Did not disclose 15 (8.2)   2 (2.2)
PCV13: Pneumococcal conjugate vaccine 13-valent.
Table 3  Carriage rate of Streptococcus pneumoniae, Neisseria 
meningitidis and Staphylococcus aureus
During Hajj Post-Hajj P 1
First day of 
Mina (NAT)
Last day of 
Mina (NAT)
Standard 
culture
S. pneumoniae 1/10 26/183 1/93 < 0.01
N. meningitidis -- 1/183 2/93 0.26
S. aureus -- -- 17/93
1P value is for the difference in carriage detection rates for the last day of Mina 
vs post-Hajj by standard culture. NAT: Nucleic acid testing; N. meningitidis: 
Neisseria meningitidis; S. pneumoniae: Streptococcus pneumoniae; S. aureus: 
Staphylococcus aureus.
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participants had taken antibiotics (either amoxicillin, 
amoxicillin/clavulanic acid and/or roxithromycin) while 
at Hajj; however, none had taken antibiotics within 2 
wk prior to swab collection. S. aureus was isolated from 
two of those who reported using antibiotics during Hajj 
and S. pneumoniae from another one.
DISCUSSION
We found a 14.2% pneumococcal carriage rate in pil-
grims during the Hajj 2014, which is moderately high. 
About 2 in 5 received conjugate pneumococcal vaccine 
before travel. Carriage was similar irrespective of whether 
pneumococcal vaccine had been given, reflecting the 
likelihood that many pilgrims were already colonised 
before being vaccinated and that vaccination is more 
potent in preventing acquisition than in extinguishing 
carriage. 
Prevalence of pneumococcal carriage was almost 
double the rate reported among French pilgrims during 
the early phase of the Hajj 2012 (7.3%), but lower 
than the rate (19.5%) found a few days before the 
pilgrims’ departure from KSA[36]. In a study of 3203 
pilgrims (1590 at the beginning, and 1613 at the end 
of Hajj), Memish et al[37] demonstrated that, although 
the overall carriage rate of pneumococci among African 
and Asian pilgrims in the early weeks of the Hajj 2011 
and 2012 was 4.4%, the prevalence of PCV13 vaccine-
serotypes was only 1.1%. In the same cross-sectional 
investigation, the overall carriage rate was 7.5% during 
the later phase of Hajj and 3.6% belonged to PCV13 
vaccine-serotypes[37]. Subsequently the investigators 
conducted a prospective cohort study during the Hajj 
2013 demonstrating that 1.8% pilgrims before and 7.1% 
(P < 0.01) pilgrims immediately after the conclusion of 
Hajj carried pneumococci; 35.5% serotypes are covered 
by PCV-13[38]. However, the carriage rates reported in 
all studies including ours, was much lower than the 
high carriage rate of 62% found by Benkouiten et al[39] 
among French pilgrims during the Hajj 2013. 
The pneumococcal carriage rate in the post-Hajj 
phase was very low (1.1%). We are unaware of any 
other pneumococcal carriage study in pilgrims after 
return to their home countries for comparison. High 
PCV13 uptake (39%) in the post-Hajj cohort may have 
reduced the carriage rate or it could be an effect of 
antibiotic use (17.2% reported receiving antibiotics while 
at Hajj). Also, there was a time difference of up to two 
months between collection of Hajj and post-Hajj samples, 
enough time for most pilgrims to have lost carriage of 
Hajj-associated pneumococci. The diagnostic tests used 
differed between our study phases (PCR was used for 
first phase, and standard culture for the second phase) 
which may explain the low detection rate in the post-Hajj 
phase.
The uptake of PCV13 in the first cohort of our study, 
21%, and in the second cohort (post-Hajj), 40.9%, 
was higher than any other report. This reflects pilgrims’ 
participation in a vaccine trial involving PCV13. However, 
we did not find significant difference in pneumococcal 
carriage rate between vaccinated and unvaccinated 
pilgrims. Although not significant, it was lower in the 
vaccinated group (Table 4), possibly because of the 
small sample size or because a large proportion of 
the serotypes were not covered by PCV13. Although 
serotype characterisation was not performed in our pilot 
study, other studies suggest that between a quarter and 
half of the serotypes at Hajj are not covered by PCV13. 
None of the pilgrims in our cohorts reported having re-
ceived pneumococcal polysaccharide vaccine, because 
only a few (3.3%) suffered from chronic diseases for 
which pneumococcal vaccination is recommended, and 
only one was aged over 65 years. In another study, 
overall pneumococcal polysaccharide vaccine uptake 
among Australian pilgrims ranged between 14% and 
29%[40]. International studies have shown that the 
overall uptake of pneumococcal vaccine in Hajj pilgrims 
ranged between 2.5% and 36%[41-43].
The low meningococcal carriage rate of 0.6% du-
ring Hajj is not surprising because of more universal 
vaccination, nearly half with quadrivalent conjugate 
vaccine. During Hajj 2012 and 2013, Benkouiten et al[39] 
failed to detect N. meningitidis in nasal and/or throat 
swabs collected from French pilgrims. However, a study 
conducted in Mina during Hajj 2003 among 344 pilgrims 
from 29 different nations identified a carriage rate of 
3.2%[44], following the 2000-2001 W epidemic.
The post-Hajj meningococcal carriage rate of 1.1% 
is less than in other studies. After the worldwide menin-
gococcal W outbreak following 2000 Hajj, the carriage 
among Singaporean pilgrims two weeks after the Hajj 
2001 was 15% for serogroup W with 55% persisting as 
carriers for 5-6 mo[45]. During the following year, El Bashir 
et al[8] demonstrated a carriage rate of 6.3% among 
United Kingdom pilgrims for all serogroups 2-6 wk after 
the pilgrims’ return from Hajj. Twenty one percent of 
the pilgrims reported receiving antibiotics for respiratory 
illnesses during Hajj[8]. This high rate of antibiotic use 
compares with 17.2% reported by participants in our study. 
In 2010, Ceyhan et al[46] reported that 27% of returned 
Turkish Hajj pilgrims were positive for meningococcal 
carriage, mostly W-135. Airport-based surveillance studies 
conducted in 2001 in Thailand[47] and the United States[48] 
demonstrated a meningococci carriage rate of 0% and 
2.6%, respectively. This is similar to the 1.4% carriage rate 
in a more contemporary study in Iran in 2012[49]. In the 
Table 4  Pneumococcal carriage rates according to the uptake 
of 13-valent pneumococcal conjugate vaccine in first phase of 
study
PCR positive for 
pneumococci n  (%)
PCR negative for 
pneumococci n  (%)
Total
PCV13   4 (10.5)   34 (89.5)   38
No PCV13 22 (15.2) 123 (84.8) 145
Total 26 (14.2) 157 (85.8) 183
PCV13: Pneumococcal conjugate vaccine 13-valent.
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latter two studies respectively, 15% and 58.5% pilgrims 
reported using antibiotics during Hajj[48,49]. Other studies 
conducted in Iran and Kuwait demonstrated that a single 
dose of ciprofloxacin before travel essentially eradicated 
meningococcal carriage[50,51]. The low carriage rate several 
weeks after Hajj in our study could possibly be indicative 
of the effect of a fairly high uptake (44.1%) of conjugate 
meningococcal vaccine. By contrast, the reported uptake 
of conjugate meningococcal vaccine among international 
pilgrims at Hajj 2013 was only 0.2%[42]. Worldwide, few 
pilgrims receive the conjugate vaccine because of its costs. 
In a surveillance study conducted in 2009 involving 1400 
Hajj pilgrims of 14 nationalities, Ashgar et al[28] found the 
carriage rate of meningococci among arriving Hajj pilgrims 
to be 5.9%, increased by the end of the pilgrimage to 
11.1% (P = 0.03)[28]. They also reported circulation 
of meningococcal strains resistant to azithromycin, 
ceftriaxone, ciprofloxacin, levofloxacin, meropenem and 
rifampicin[28].
Due to the public health significance, monitoring 
of antimicrobial susceptibility of clinical specimens 
for meningococci and pneumococci is important[52], 
particularly since pilgrims from high-risk countries in 
the African meningitis belt are routinely given cipro-
floxacin prophylaxis on arrival for pilgrimage into KSA. 
Transnational dissemination of multi-drug resistant 
organisms has been reported[28]. This is relevant in the 
context of pneumococcal disease since about 20% of the 
pneumococcal isolates at Hajj are penicillin resistant[53]. 
Circulation of drug resistant pneumococci has been 
of concern in other mass gatherings, such as the 
reporting of pathogenic multi-drug resistant strains of S. 
pneumoniae circulating in Spain at the time of Barcelona 
Olympic in 1992 (however, the Olympic Organising 
Committee did not recommend pneumococcal vaccine for 
visitors)[54,55]. Today, antibiotic resistance is widespread 
and, considering the high incidence of pneumonia, the 
high carriage rate of pneumococci and circulation of 
multi-drug-resistant pneumococci, vaccination is recom-
mended for all high-risk pilgrims and the conjugate 
vaccine is preferred[20,37,53]. 
The effect of facemasks use on pharyngeal bacterial 
carriage at Hajj has not been established yet, although 
a large trial is underway to examine the effectiveness of 
facemasks against viral infections[32]. In other settings 
such as among healthcare workers, the effectiveness 
of facemasks against pharyngeal bacterial colonisation, 
including S. pneumoniae was evaluated but no significant 
effect was observed[56]. Even though we did not find any 
significant effect of facemasks use on the pharyngeal/
nasopharyngeal carriage rate of S. pneumoniae or S. 
aureus, interestingly a prospective study conducted in 
the Netherlands among pig farmers demonstrated that 
the use of facemasks was significantly associated with 
lower MRSA nasal carriage[57]. Perhaps a larger facemask 
study could demonstrate its true effect on pharyngeal 
colonisation of bacteria. We found an 18% carriage 
rate of S. aureus in the second (post-Hajj) phase of the 
study, but did not detect MRSA. This compares with a 
nasal carriage rate of 25% among arriving international 
pilgrims and 20.9% among departing pilgrims during 
the Hajj 2009[58] and similar to the nasal carriage rate 
of methicillin-susceptible S. aureus (28%) elsewhere in 
Australia[59,60].
To our knowledge, this is the first Australian carriage 
surveillance study for potentially pathogenic bacteria such 
as pneumococci, meningococci and S. aureus among 
Hajj pilgrims. We were able to validate pneumococcal and 
meningococcal conjugate vaccine uptake from a parallel 
trial. In the Hajj 2009, roughly one in five to seven 
S. aureus isolates were MRSA[58]. S. aureus has been 
cultured from sputum samples (between 3.8% to 7.7% 
isolates) among Hajj pilgrims with respiratory infections 
but MRSA was not cultured[15,59]. However, MRSA was 
isolated in samples collected from various body sites in 
about 1.5% pilgrims during the Hajj 2004[22]. 
Limitations of our study include a relatively small 
sample size and an inconsistent sampling site (i.e., mostly 
nasopharyngeal in the first phase and oropharyngeal in 
the second phase). Different diagnostic methods were 
employed in the two different phases of the study with 
NAT in first phase of the study and phenotypic methods 
in the second phase which did not allow us to compare 
two datasets directly, and because of the differences 
in study designs it was not possible to make valid 
comparison with the reports of other investigators, so 
we limited the discussion to only narrative synthesis. In 
addition, only a few strains of carriage organisms were 
studied, especially we did not assess for other potentially 
vaccine preventable pathogens such as H. influenza, 
and pneumococcal isolates were not serotyped. The 
discordance in the number of participants between first 
and second phase was due to unavailability of some 
participants for post-Hajj sampling within 2 mo after 
Hajj, because often pilgrims make side trips to other 
countries after Hajj and do not return to Australia directly. 
To address these limitations, a larger study is currently 
underway.
In conclusion, this study found a moderately high 
carriage rate of S. pneumoniae amongst pilgrims during 
the Hajj 2014 in the background of a conjugate pneu-
mococcal vaccine trial, but a low meningococcal carriage 
rate. This pilot study demonstrates that a larger study is 
feasible and important to inform public health measures to 
prevent the transmission and limit the impact of significant 
infectious diseases at mass gathering events such as 
the annual Hajj pilgrimage. Further information on the 
serotype of circulating pneumococcal isolates will optimise 
the use of pneumococcal vaccination in pilgrims. 
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